Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOG NASDAQ:CRDF NASDAQ:MOLN NASDAQ:XLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$9.80+0.2%$9.31$3.75▼$11.54$158.05M2.7170,700 shs62,727 shsCRDFCardiff Oncology$2.05-1.4%$2.87$1.90▼$5.64$138.37M1.281.10 million shs616,958 shsMOLNMolecular Partners$3.68-2.0%$3.70$3.36▼$7.60$151.40M1.15,040 shs2,286 shsXLOXilio Therapeutics$0.74+0.9%$0.70$0.62▼$1.70$37.82M-0.14917,982 shs408,590 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition+0.20%+10.11%-1.90%+4.81%+979,999,900.00%CRDFCardiff Oncology-1.44%-5.53%-16.33%-46.19%-11.26%MOLNMolecular Partners-1.58%+2.68%-0.14%-5.04%-30.51%XLOXilio Therapeutics+0.95%+5.26%+3.06%+11.20%-4.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$9.80+0.2%$9.31$3.75▼$11.54$158.05M2.7170,700 shs62,727 shsCRDFCardiff Oncology$2.05-1.4%$2.87$1.90▼$5.64$138.37M1.281.10 million shs616,958 shsMOLNMolecular Partners$3.68-2.0%$3.70$3.36▼$7.60$151.40M1.15,040 shs2,286 shsXLOXilio Therapeutics$0.74+0.9%$0.70$0.62▼$1.70$37.82M-0.14917,982 shs408,590 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition+0.20%+10.11%-1.90%+4.81%+979,999,900.00%CRDFCardiff Oncology-1.44%-5.53%-16.33%-46.19%-11.26%MOLNMolecular Partners-1.58%+2.68%-0.14%-5.04%-30.51%XLOXilio Therapeutics+0.95%+5.26%+3.06%+11.20%-4.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$20.00104.08% UpsideCRDFCardiff Oncology 2.80Moderate Buy$10.63418.29% UpsideMOLNMolecular Partners 3.00Buy$8.00117.63% UpsideXLOXilio Therapeutics 3.33Buy$3.00307.28% UpsideCurrent Analyst Ratings BreakdownLatest XLO, MOLN, CRDF, and ACOG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025MOLNMolecular PartnersJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$4.50 ➝ $4.008/6/2025CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $10.008/6/2025XLOXilio TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/6/2025XLOXilio TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$2.007/8/2025CRDFCardiff OncologyLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$19.006/24/2025CRDFCardiff OncologyJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold$3.506/18/2025CRDFCardiff OncologyWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha CognitionN/AN/AN/AN/A$2.59 per shareN/ACRDFCardiff Oncology$680K200.57N/AN/A$1.86 per share1.10MOLNMolecular Partners$5.65M26.27N/AN/A$3.99 per share0.92XLOXilio Therapeutics$6.34M6.02N/AN/A$0.40 per share1.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$14.64M-$1.60N/A∞N/AN/A-80.16%-60.95%11/13/2025 (Estimated)CRDFCardiff Oncology-$45.43M-$0.87N/AN/AN/A-9,344.14%-77.94%-63.65%11/6/2025 (Estimated)MOLNMolecular Partners-$61.39M-$2.08N/AN/AN/AN/A-50.66%-45.13%10/30/2025 (Estimated)XLOXilio Therapeutics-$58.24M-$0.76N/AN/AN/A-374.79%-399.15%-58.68%11/6/2025 (Estimated)Latest XLO, MOLN, CRDF, and ACOG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/25/2025H1 2025MOLNMolecular Partners-$0.53-$0.67-$0.14-$0.67N/AN/A8/14/2025Q2 2025ACOGAlpha Cognition-$0.46-$0.65-$0.19-$0.65$2.32 million$1.66 million8/14/2025Q2 2025XLOXilio Therapeutics-$0.08-$0.16-$0.08-$0.16$8.21 million$8.21 million7/29/2025Q2 2025CRDFCardiff Oncology-$0.19-$0.21-$0.02-$0.21$0.11 million$0.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/AXLOXilio TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A17.1416.83CRDFCardiff OncologyN/A4.424.42MOLNMolecular PartnersN/A9.359.35XLOXilio TherapeuticsN/A2.322.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/ACRDFCardiff Oncology16.29%MOLNMolecular Partners26.55%XLOXilio Therapeutics54.29%Insider OwnershipCompanyInsider OwnershipACOGAlpha Cognition14.00%CRDFCardiff Oncology7.70%MOLNMolecular Partners5.93%XLOXilio Therapeutics5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A16.16 million13.90 millionN/ACRDFCardiff Oncology2066.53 million61.40 millionOptionableMOLNMolecular Partners18040.38 million37.98 millionNot OptionableXLOXilio Therapeutics7051.83 million49.13 millionNot OptionableXLO, MOLN, CRDF, and ACOG HeadlinesRecent News About These CompaniesXilio Therapeutics sees cash runway into 1Q27September 9, 2025 | msn.comXilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under ...September 9, 2025 | finance.yahoo.comXilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with GileadSeptember 9, 2025 | globenewswire.comXilio Therapeutics (XLO) Has a New Rating from Leerink PartnersAugust 29, 2025 | theglobeandmail.comXilio Therapeutics Faces Nasdaq Equity Compliance ChallengeAugust 28, 2025 | tipranks.comXLO | Xilio Therapeutics Inc. Annual Cash Flow Statement | MarketWatchAugust 16, 2025 | marketwatch.comXilio Therapeutics reports Q2 EPS (16c) vs (24c) last yearAugust 15, 2025 | msn.comXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial ResultsAugust 15, 2025 | taiwannews.com.twTXilio Revenue Jumps 246 Percent in Q2August 15, 2025 | aol.comAXilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue EstimatesAugust 14, 2025 | zacks.comXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial ResultsAugust 14, 2025 | globenewswire.comLeerink Partners Initiates Coverage of Xilio Therapeutics (XLO) with Outperform RecommendationAugust 7, 2025 | msn.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 3, 2025 | morningstar.comMXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 | globenewswire.comJames Samuel Shannon Acquires 25,000 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) StockJune 19, 2025 | insidertrades.comXilio Therapeutics expands board, elects new directorJune 12, 2025 | investing.comXilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of DirectorsJune 10, 2025 | quiverquant.comQXilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of DirectorsJune 10, 2025 | globenewswire.comXilio Therapeutics Announces Closing of $50.0 Million Public OfferingJune 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXLO, MOLN, CRDF, and ACOG Company DescriptionsAlpha Cognition NASDAQ:ACOG$9.80 +0.02 (+0.20%) As of 09/12/2025 04:00 PM EasternAlpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.Cardiff Oncology NASDAQ:CRDF$2.05 -0.03 (-1.44%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.08 +0.04 (+1.71%) As of 09/12/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Molecular Partners NASDAQ:MOLN$3.68 -0.07 (-1.97%) Closing price 09/12/2025 03:56 PM EasternExtended Trading$3.72 +0.04 (+1.20%) As of 09/12/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Xilio Therapeutics NASDAQ:XLO$0.74 +0.01 (+0.95%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.74 0.00 (-0.22%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
